Daniel P. Petrylak, MD, presented “Phase 1 Trial of ARV-110 in Patients with mCRPC” for the Grand Rounds in Urology audience in June, 2020.
How to cite: Petrylak, Daniel P. “Phase 1 Trial of ARV-110 in Patients with mCRPC” June, 2020. Accessed Dec 2024. https://dev.grandroundsinurology.com/phase-1-trial-of-arv-110-in-patients-with-mcrpc/
Phase 1 Trial of ARV-110 in Patients with mCRPC – Summary:
Daniel P. Petrylak, MD, Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center, discusses promising new developments coming out of a trial that interferes with the androgen receptor and degrades it. Phase 1 of this trial looks at ARV-110 in patients with mCRPC and Dr. Petrylak highlights why the study’s recent findings are so exciting. He goes into detail the study methodology and how ARV-110 works in comparison to traditional treatments. Dr. Petrylak also explains why the findings are so promising and what the next steps are for the study.
To expand your knowledge of androgen deprivation therapy, visit our ADT Next Generation Learning Center.
ABOUT THE AUTHOR
Daniel P. Petrylak, MD, is currently Director of Genitourinary Oncology, Professor of Medicine and Urology, Co-Leader of Cancer Signaling Networks, and Co-Director of the Signal Transduction Program at Yale University Cancer Center in New Haven, Connecticut. He is a recognized international leader in the urology field. He earned his MD at Case Western Reserve University School of Medicine in Cleveland Ohio. He then went on to complete his Internal Medicine Residency at Albert Einstein College of Medicine/Jacobi Medical Center in the Bronx, and his fellowship at Memorial Sloan Kettering Cancer Center in New York.
Dr. Petrylak has served as principal investigator (PI) or co-PI on several SWOG clinical trials for genitourinary cancers. Most notably, he served as the PI for a randomized trial that led to the FDA approval of docetaxel in hormone refractory prostate cancer. He also helped to design and served as PI for the SPARC trial, an international registration trial evaluating satraplatin as a second-line therapy for hormone refractory prostate cancer.
Dr. Petrylak served on the program committees for the annual meetings of the American Urological Association from 2003-2011, and for the American Society of Clinical Oncology from 1995-1997 and 2001-2003. He also has served as a committee member for the Devices and Immunologicals section of the FDA. He has published extensively in the New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, Cancer Research, and Clinical Cancer Research.
